

S&K Therapeutics

Category	Enterprise Creation
○ Corporation (Preliminary Enterprise)	S&K Therapeutics
○ Representative	Choi Sangdun
○ Establishment year	2020
○ Specialized Field	Development of medicines for autoimmune diseases and inflammatory diseases
○ Address	Woncheon-gwan 135, Ajou University, Worldcup-ro 206, Yeongtong-gu, Suwon-si, 16499, Gyeonggi-do
○ Home page	- Homepage: http://www.snktherapeutics.com
○ Enterprise Brief Introduction	- S&K Therapeutics is focusing its core capabilities on developing new small molecule drugs to meet the unmet medical needs, and aims to develop new medicines for systemic lupus erythematosus, rheumatoid arthritis, psoriasis, Alzheimer's and diabetes.
○ Product and Pipeline Introduction	- S&K Therapeutics owns an artificial intelligence-based drug development platform that allows to discover new molecular entities effectively. Furthermore, based on extensive research experience on TLRs (Toll-like receptors), S&K therapeutics possesses new drug development pipelines for autoimmune diseases, inflammatory diseases, and viral diseases.
○ Patent and Certification, Licensing, Thesis, Investment status, etc.	Patent Applications: KR10-2020-0160977 (2020.11.26) KR10-2020-0126710 (2020.09.29) KR10-2021-0015425 (2021.02.03)